Five-Year Dosing, Efficacy Results for Nab-Paclitaxel in TNBC
Hope S. Rugo, MD, a medical oncologist and Director of the Breast Oncology Clinical Trials Program at University of California San Francisco Helen Diller Family Comprehensive Cancer Center, discusses 5-year follow-up data from the CALGB 40502//NCCTG N063H study, which was a randomized phase III trial of weekly paclitaxel (Abraxane) compared with nab-paclitaxel or ixabepilone (Ixempra) with bevacizumab (Avastin) as first-line chemotherapy for locally recurrent or metastatic breast cancer.
Hope S. Rugo, MD, a medical oncologist and director of the Breast Oncology Clinical Trials Program at University of California, San Francisco, Helen Diller Family Comprehensive Cancer Center, discusses 5-year follow-up data from the CALGB 40502/NCCTG N063H study, which was a randomized phase III trial of weekly paclitaxel compared with nab-paclitaxel (Abraxane) or ixabepilone (Ixempra) with bevacizumab (Avastin) as first-line chemotherapy for locally recurrent or metastatic breast cancer.
At the 4-year median follow-up, the overall results demonstrated inferiority of the ixabepilone arm for both progression-free survival (PFS) and overall survival (OS). Similar results were seen with nab-paclitaxel.
However, a subset analysis showed a trend toward superiority of nab-paclitaxel versus paclitaxel in the triple-negative breast cancer (TNBC) group. In the hormone receptor-positive (HR+) group, investigators found nab-paclitaxel and ixabepilone to be inferior to paclitaxel.
For OS, ixabepilone was inferior, while nab-paclitaxel trended toward inferior in the HR+ subset, although ixabepilone was quite superior for PFS, at 21 months versus 15 months, in the TNBC group.
Peers Discuss Sacituzumab Govitecan in HR+ mBC Post Endocrine Therapy
July 24th 2024During a Case-Based Roundtable® event, Tiffany A. Traina, MD, surveyed participants on treatment for a patient who had progressed following endocrine therapy for metastatic breast cancer in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
